Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986.8 GBX 1.11% Market Closed
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Smith & Nephew PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Smith & Nephew PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
Cash from Financing Activities
$258m
CAGR 3-Years
-22%
CAGR 5-Years
21%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash from Financing Activities
$17m
CAGR 3-Years
N/A
CAGR 5-Years
-32%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Cash from Financing Activities
-ÂŁ7.1m
CAGR 3-Years
-10%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Angle PLC
LSE:AGL
Cash from Financing Activities
ÂŁ7.8m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Cash from Financing Activities
ÂŁ4.7m
CAGR 3-Years
720%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cash from Financing Activities
$12.5m
CAGR 3-Years
80%
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC has a rich history dating back to 1856, evolving from a small medical supplies company in the UK to a prominent global player in the medical technology industry. The company specializes in advanced wound management, surgical devices, and orthopedic reconstruction, driven by a mission to restore people’s bodies and health, enabling them to live life to the fullest. As an investor, you’ll find that Smith & Nephew stands out for its commitment to innovation, consistently investing a significant portion of its revenue into research and development. This dedication results in a robust pipeline of cutting-edge products, such as its highly regarded advanced wound care solutions and knee and hip reconstruction devices. The company’s strategic focus on emerging markets and partnerships with healthcare providers positions it well for sustainable growth amid shifts in the global healthcare landscape. Navigating the complexities of the healthcare sector, Smith & Nephew demonstrates resilience through its diversified product range and broad geographic presence, generating revenue from both developed and developing markets. The company has been enhancing its operational efficiency, improved profit margins, and reduced costs, which resonate well with value investors seeking financially sound opportunities. Furthermore, the company’s commitment to environmental, social, and governance (ESG) principles may appeal to socially conscious investors. As Smith & Nephew continues to leverage technological advancements and respond to the evolving needs of healthcare systems, its story remains compelling – offering not just potential financial returns but also a commitment to improving patient outcomes and enhancing the quality of life around the globe.

SN Intrinsic Value
1 458.57 GBX
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Smith & Nephew PLC's Cash from Financing Activities?
Cash from Financing Activities
258m USD

Based on the financial report for Jun 29, 2024, Smith & Nephew PLC's Cash from Financing Activities amounts to 258m USD.

What is Smith & Nephew PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
21%

The average annual Cash from Financing Activities growth rates for Smith & Nephew PLC have been -22% over the past three years , 21% over the past five years .

Back to Top